Rivaroxaban receives a licence in the UK for the prevention of stroke for people with non-valvular atrial fibrillation and for the treatment of deep vein thrombosis (DVT) and for the prevention of recurrent DVT and pulmonary emoblism

• Xarelto becomes the first once-daily, fixed-dose preventative treatment for UK patients with non-valvular atrial fibrillation (AF) at risk of the devastating consequences of stroke, without the need for routine coagulation monitoring
• For the treatment of DVT and prevention of recurrent DVT and PE in adult patients following an acute DVT, Xarelto is the first and only oral anticoagulant to offer patients and the NHS a convenient and cost-effective single-drug solution
• Xarelto is now approved in the UK across three indications